(Q58369400)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17366652%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

title

ESI-MS characterisation of protein adducts of anticancer ruthenium(II)-arene PTA (RAPTA) complexes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17366652%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17366652%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Guido Mastrobuoni

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17366652%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Wee Han Ang

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17366652%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Chiara Gabbiani

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17366652%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Giuseppe Pieraccini

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17366652%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Paul Dyson

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17366652%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Luigi Messori

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17366652%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

author name string

Gloriano Moneti

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17366652%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

publication date

1 May 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17366652%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17366652%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17366652%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

page(s)

631-635

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17366652%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17366652%20AND%20SRC:MED&resulttype=core&format=json

Ruthenium antimetastatic agents

27 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600258

7 January 2021

A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600258

7 January 2021

Recent developments in the field of tumor-inhibiting metal complexes.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600258

7 January 2021

From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600258

7 January 2021

Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600258

7 January 2021

Classical and Non-Classical Ruthenium-Based Anticancer Drugs: Towards Targeted Chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600258

7 January 2021

Metal-based antitumour drugs in the post genomic era.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600258

7 January 2021

Inhibition of the MEK/ERK signaling pathway by the novel antimetastatic agent NAMI-A down regulates c-myc gene expression and endothelial cell proliferation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600258

7 January 2021

A mass spectrometric and molecular modelling study of cisplatin binding to transferrin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600258

7 January 2021

ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600258

7 January 2021

Interactions of cisplatin and transplatin with proteins. Comparison of binding kinetics, binding sites and reactivity of the Pt-protein adducts of cisplatin and transplatin towards biological nucleophiles

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600258

7 January 2021

Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600258

7 January 2021

In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600258

7 January 2021

Cytochrome C-mediated apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600258

7 January 2021

Lysozyme and alpha-lactalbumin: structure, function, and interrelationships

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600258

7 January 2021

Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600258

7 January 2021

Binding of Organometallic Ruthenium(II) and Osmium(II) Complexes to an Oligonucleotide: A Combined Mass Spectrometric and Theoretical Study†

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600258

7 January 2021

Influence of Hydrogen-Bonding Substituents on the Cytotoxicity of RAPTA Compounds

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600258

7 January 2021

Exploring Metallodrug–Protein Interactions by ESI Mass Spectrometry: The Reaction of Anticancer Platinum Drugs with Horse Heart Cytochrome c

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600258

7 January 2021

Competitive reactions of a ruthenium arene anticancer complex with histidine, cytochrome c and an oligonucleotide

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600258

7 January 2021

Half-sandwich arene ruthenium(II)-enzyme complex

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600258

7 January 2021

Binding of ruthenium(III) anti-tumor drugs to human lactoferrin probed by high resolution X-ray crystallographic structure analyses

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600258

7 January 2021

A comparative study of adduct formation between the anticancer ruthenium(III) compound HInd trans-[RuCl4(Ind)2] and serum proteins.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600258

7 January 2021

A spectroscopic study of the reaction of NAMI, a novel ruthenium(III)anti-neoplastic complex, with bovine serum albumin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600258

7 January 2021

Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600258

7 January 2021

Preparation and characterization of a pentaammineruthenium(III) derivative of horse heart ferricytochrome c

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600258

7 January 2021

[Ru(η6-p-cymene)Cl2(pta)] (pta = 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane): a water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600258

7 January 2021

Identifiers

DOI

10.1002/CMDC.200600258

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17366652%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference